ArticleSurgical endoscopy2026
Endoscopic ultrasound-guided biliary drainage is cost-effective for treatment of malignant distal biliary obstruction after failed ERCP.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndoscopic ultrasound (EUS)-guided biliary drainage is a promising alternative for malignant distal biliary obstruction (MDBO) after failed endoscopic retrograde cholangiopancreatography (ERCP). This study evaluates the cost-effectiveness of EUS-guided gallbladder drainage (EUS-GB) and EUS-guided choledochoduodenostomy (EUS-CBD) compared to percutaneous transhepatic biliary drainage (PTBD) in these patients.
methodsA decision analysis model compared costs and quality-adjusted life years (QALYs) over two years for patients with MDBO after failed ERCP, undergoing EUS-GB, EUS-CBD, or PTBD. Incremental cost-effectiveness ratios (ICERs) and net monetary benefits (NMBs) were calculated at a willingness-to-pay threshold of $100,000 per QALY. Probabilistic and deterministic sensitivity analyses were performed.
resultsBoth EUS-GB and EUS-CBD were more cost-effective than PTBD. PTBD cost $14,988, EUS-GB cost $14,520 (adding 0.38 QALYs and $37,768 incremental NMB), and EUS-CBD cost $17,694 (adding 0.55 QALYs and $52,171 incremental NMB). Although PTBD had the lowest cost, it was dominated due to fewer QALYs. Results were robust in sensitivity analyses.
conclusionEUS-GB and EUS-CBD are more cost-effective than PTBD for MDBO after failed ERCP. EUS-GB offers similar value to EUS-CBD, potentially with lower reintervention rates. Endoscopic management should be prioritized over PTBD for these patients.
Indexed as
Identifiers
41131378What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.